HC Wainwright reiterated their buy rating on shares of Beyondspring (NASDAQ:BYSI) in a research report sent to investors on Wednesday morning, Briefing.com Automated Import reports. They currently have a $60.00 target price on the stock.
Separately, Maxim Group reissued a buy rating and set a $58.00 price target on shares of Brinker International in a research report on Tuesday, April 30th.
Shares of BYSI opened at $20.70 on Wednesday. The company’s 50-day moving average is $19.20. Beyondspring has a 1-year low of $13.06 and a 1-year high of $26.98.
Beyondspring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Read More: Percentage Gainers
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.